Macrolide antibiotics in the treatment of asthma. An update

Allergologia et Immunopathologia

Volumn 38, Issue 2, 2010, Pages 92-98

  Hernando Sastre, V ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Antibiotics; Asthma; Erythromycin; Macrolides; Treatment

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; DIRITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; MIDECAMYCIN; MONTELUKAST; PLACEBO; ROXITHROMYCIN; SPIRAMYCIN; TELITHROMYCIN; TROLEANDOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION SENSITIVITY; LIVER TOXICITY; LONG TERM EXPOSURE; LOW DRUG DOSE; MYCOPLASMA PNEUMONIAE; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; IMMUNOLOGIC FACTORS; MACROLIDES; MYCOPLASMA PNEUMONIAE; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRUS DISEASES;

EID: 77951092647     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2009.12.002     Document Type: Review

References (66)

1. Mc Guire J.M. Ilotrycin: a new antibiotic. Antibiotics and chemotherapy 1952, 2:281.
2. Oliva M., García J.A. Eritromicina. Descubrimiento, características y aplicaciones. Farmacología 2002, 21:78-82.
3. Betancour J. Nuevos macrólidos. Rev CES Med 1993, 7:95-97.
4. Sánchez F., Sánchez J. Antibióticos macrólidos (antualizació). Medicine 2006, 9:3591-3596.
5. Mazzei T., Mini E., Novelli A., Penti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993, 31(supp C):1-9.
6. er congreso mundialde enfermedades infecciosas en pediatría 1996, Libro de comunicaciones, Acapulco (Mexico).
7. Westphal J.F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP)3A4: an update focused on Clarithromicyn, Azithromycin and Dirithromycin. J Clin Pharmacol 2000, 50:285-295.
8. Corne J.M., Marshall C., Smith S., Schreiber J., Sanderson G., Holgate S.T., et al. Frequency, severity and duration of rhinovirus infections in asthmaticsand non-asthmatic individuals: a longitudinal study. Lancet 2002, 359:831-834.
9. Wark P.A., Johnston S.L., Buchieri F., Powell R., Puddicombe S., Laza-Stanca V., et al. Astrhmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005, 201:937-947.
10. Johnston S.L., Pattemore P.K., Sanderson G., smith S., Lampe F., Josepphs L., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 years old children. BMJ 1995, 310:1225-1229.
11. Wark P.A.B., Johnston S.L., Moric I., simpson J.L., Hensley M.J., Gibson P.G. Neutrophil degranulation and cells lysis is associated with clinical severity in virus induced asthma. Eur Respir J 2001, 19:68-75.
12. Sykes A.M., Johnston S.L. Etiology of asthma exacerbations. J Allergy clin Immunol 2008, 122:685-688.
13. Papadopoulos N.G., Papi A., Psarsas S., Johnston S.L. Mechanisms of rhinovirus induced asthma. Paediatr Respir Rev 2004, 5:255-260.
14. Barlett N.W., Walton R.P., Edwards M.R., Aniscenko J., Caramon G., Zhu J., et al. Mouse models of rhinovirus-induced disease and exacerbations of allergic airway inflammation. Nat Med 2008, 14:199-204.
15. Cunningham A.F., Johnston S.L., Julions S.A., Lampe F.C., Ward M.E. Chronic Chlamydia Penumonie infection and asthma exacerbations in children. Eur Respir J 1998, 11:345-349.
16. Wark P.A.B., Johnston S.L., Simpson J.L., Hensley M.J., Gibson P.G. Chlamydia Pneumonie immunoglobulin A reactivation and aiway inflammation in acute asthma. Eur Respir J 2002, 20:834-840.
17. Kaukoranta-Tolvanen S.S., Teppo A.M., Laitinen K., Saikku P., Limavuori K., Leinonen M. Grwth of Chlamydia Pneumonie in cultived human peripheral blood mononuclear cells and infection induction of a citokine esponse. Microb Pathog 1966, 21:215-221.
18. Redecke V., Dalhoff K., Bohnet S., Braun J. Maas M. Interaction of Chlamydia Pneumonie and human alveolar macrophages.
19. Blasi F., Aliberti S., Allegra L., Piatti G., Tarsia P., Ossewaardl J.M., et al. Chlamydia Pneumonie inducer a sustained airway hiperresponsiveness and inflammation in mice. Respir Res 2007, 19:83.
20. Talbot T.R., Hartert T.V., Mitchel E., Halasa N.B., Arbogart P.G., Poehling K.A., et al. Asthma as a risk factor for invasive pneumoccocal disease. N Eng J Med 2005, 352:2082-2090.
21. Martin R.J., Kraft M., Chu H.W., Barns E.A., Cassell G.H. A link between cronic asthma and cronic infection. J Allergy Clin Immunol 2001, 107:595-601.
22. Brisccione G.L., Corne J., Chauchan A.J., Johnston S.L. Increased frquency of detection of C. Pneumonie in asthma. Eur Respir J 2004, 24:745-749.
23. Johnston S.L., Martin R.J. Chlamydophila Pneumonie and Mycoplasma Pneumonie: A role in asthma pathogenesis. Am J Respir Crit Care Med 2005, 172:1078-1089.
24. 2) and the severity of virus-induced asthma in children. Lancet 2003, 361:1939-1944.
25. Wark P.A., Johnston S.L., Moric I., Simpson J.L., Henseley M.J., Gibson P.G. Neutrophil degranmulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002, 19:68-75.
26. Kudoh S., Netake T., Hagiwara K., et al. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987, 25:632-642.
27. Junichi K., Mukae H., Tomono K., Kohno S., Nasu M. Efficacy on lon-term mcrolide antibiotic therapy in patients with diffuse panbronchiolitis: Comparison between HLA-B54 positive and negative cases. Inter J Antimicrob Agents 2004, 24:550-554.
28. Piacentini G.L., Peroni D.G., Bodini A., Pigozzi R., Castella S., Laicono A., Boner A.L. Azitromycin reduces bronchial hiperresponsiveness and neurtrophilic airway inflammation in asthmatic childre: a preliminary rport. Allergy Asthma Proc 2007, 28:194-198.
29. Tamaoki J., Tagaya E., Sakai A., Konno K. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995, 95:853-859.
30. Shimizhu T., Shimizhu S., Hattori R., et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretio in airway epithelial cells. Am J Respir Crit Care Med 2003, 168:581-587.
31. Tagayu E., Tamaoki J., Kondo M., et al. Effect of short course of Clarithromycin therapy on sputum prduction in patients with chronic airway hypersecretion. Chest 2002, 122:213-218.
32. Yanaghigara K., Tomono K., Imamura Y., et al. Effect of Clarithromycin on chronic respiratory infection caued by Pseudomonas Aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 2002, 49:867-870.
33. Mitsuyama T., Tanaka T., Hidaka K., et al. Inhibition by Erythromycin of superoxide anion production by human polimorphonuclear leukocytes through the action of cyclic AMP-dependent protein kinasa. Respiration 1995, 62:269-273.
34. Kamoi H., Kurihara N., Fujiwara H., et al. The macrolide antibacterial Roxithromycin reduce bronchial pyperresponsiveness and superoxide anion production by polimorphonuclear leukocytes in patients with asthma. J Asthma 1995, 32:191-197.
35. Aoshiba K., Nagai A., Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995, 39:872-877.
36. Yamaryo T., Oishi K., Yoshimine H., et al. Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis af apoptoptic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 2003, 47:48-53.
37. Aoki Y., Kao P.N. Erithromycin inhibits transcripptional activation of NF-kappaB, but no NFAT, through calcineurin-independent signaling. Antimicrob Agents Chemother 1999, 43:2678-2684.
38. Desaki M., Takizawa H., Ohtashi T., et al., Erythromycin supresses nuclear factor-kapaΒ and activator proteins activation in human bronchus epithelial cells. Biochem Biophys Res Commun 200;267:124-8.
39. Kahir O.A., Devalia J.L., Abdelaziz M.M., Sapsford R.J., Davies R.J. Effect of Erythromycin on Haemophilus Influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995, 8:1451-1457.
40. Sato E., Nelson D.K., Koyama S., et al. Erythromycin modulates eosinophil chemotactic cytokine production by human lung phibroblasts in vitro. Antimicrob Agents Chemother 2001, 45:401-406.
41. Suzaki H., Asano K., Ohki S., et al. Suppresive activity of a macrolide antibiotic Roxithrmycin on pro-inflammatory cytokine production in-vitro and in-vivo. Mediators Inflamm 1999, 8:199-204.
42. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004, 125:41S-51S.
43. Shinkai M., Mo Henke, Rubin B.K. Macrolide Antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008, 117:393-405.
44. Culic O., Erakovic V., Cepelak I., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002, 450:277-289.
45. Yamasaki T. Adherence of a Pseudomonas Aeruginosa to mouse tracheal epithelium: the effect of antimicrobial agents. Kansenshogaku Zasshi 1990, 64:575-583.
46. Maziak W., Loukides S., Koyama S., et al. Exhaled nitric oxide in chronic obstuctive pulmonary disease. Am J Respir Crit Care Med 1998, 157:998-1002.
47. Meurs H., Maarsingh H., Zaagsma J. Arginasa and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci 2003, 24:450-455.
48. Sharma S., Jaffe A., Dixon G. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fobrosis. Paediatr Drug 2007, 9:107-118.
49. Tsai W.C., Standiford T.J. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. Curr Pharm Des 2004, 10:3081-3093.
50. Sutherland E.R., Martin R.J. Asthma and atypical bacterial infection. Chest 2007, 132:1962-1966.
51. Richeldi L., Ferrara G., Fabbri L.M., Gibson P.G. Macrolides for chronic asthma (cochrane review) The Cochrane Librery, Issue 1. Oxford: Update sofware;2003.
52. Nelson H.S., Hamilos D.L., Corsello P.R., Levesque N.V., Buchmeier A.D. Bucker BL. A double-blind study of troleandomycin and metyl-prednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993, 147:398-404.
53. Kamada A.K., Hill M.R., Iklé D.N., Brenner A.M., Szefler S.L. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993, 91:873-882.
54. Shoji T., Yoshida S., Sakamoto H., Hasegawa H., Nakagawa H., Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999, 29:950-956.
55. Amayasu H., Yashida S., Ebana S., Yamamoto Y., Nishikawa T., Shoji T., et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asth Immunol 2000, 84:594-598.
56. Black P., Jenkins C.R., Scicchitano R., Blasi F., Allegra L., Mills G., et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia Pneumonie. Am J Respir Crit Care Med 2001, 164:536-541.
57. Richeldi L., Ferrara G., Fabbri L., Lasserson T.J., Gibson P.G. Macrolides for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. Oxford: Update sofware; 2005.
58. Kraft M., Cassell G.H., Pak J., Martin R.J. Mycoplasma Pneumonie and Chlamydia Penumonie in asthma:effect of claritromycin. Chest 2002, 121:1782-1788.
59. Kostadima E., Tsiodras S., Alexopoulos E.I., Kaditis A.G., Mavrou I., Georgatou N., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004, 23(5):714-717.
60. Hahn D.L., Plane M.B., Mahdi O.S., Byrne G.I. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLOS clinical trials 2006, e11:1-9.
61. Godfried M.H. Macrolide for the treatment of chronic sinusitis, asthma and COPD. Chest 2004, 125:52-61.
62. Johnston S.L., Blasi F., Black P.N., et al. The effecto of Telithromycin in acute exacerbations of asthma. N Eng J Med 2006, 354:1589-1600.
63. Sturnk R.C., Bacharier L.B., Philips B.R., Szefler S.J., Zeiger R.S., Chinchilli V.M., Martínez F.D., et al. Azithromycin or Montelukast as inhaled corticosteroid-sparing agents in moderate to severe chilhood astma study. J Allergy Clin Immunol 2008, 122:1138-1144.
64. Beigelman A., Gunsten S., Milols C.L., Vidavsky I., Cannon C.L., Brody S.L., Walter M.J. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009, 136:498-506.
65. Kozyrskyj A.L., Dahl M.E., Ungar W.J., Becker A.B., Law B.J. Antibiotic treatment of wheezing in children with asthma:what is the practice?. Pediatrics 2006, 117(6):e1104-e1110.
66. Pennie R.A. Prospective study of antibiotic prescribing for children. Can Fam Physician 1998, 44:1850-1856.